Although significant variation in care persists, underuse and misuse of adjuvant endocrine therapy for breast cancer has decreased since 2004.
Letrozole was not superior to anastrazole with respect to efficacy or safety in postmenopausal women with HR-positive, node-positive early breast cancer.
Greater negative beliefs regarding the challenges of their aromatase inhibitor treatment more likely to lead to nonadherence.
Oncology nurses can play a pivotal role in diagnosis and management of the rare neuroendocrine tumors pheochromocytomas and paragangliomas.
The risk of the most serious cardiovascular events, including cardiac ischemia and stroke, was not higher for breast cancer survivors who received an aromatase inhibitor (AI) compared with tamoxifen users.
The impact on quality of life for patients with breast cancer receiving adjuvant endocrine therapy (ET) should be given more attention, and clinicians should make better efforts to address patient-reported outcomes.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|